fluoxetine has been researched along with selegiline in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.00) | 18.7374 |
| 1990's | 14 (35.00) | 18.2507 |
| 2000's | 17 (42.50) | 29.6817 |
| 2010's | 7 (17.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bergström, F; Giordanetto, F; Rehngren, M; Tunek, A; Wan, H | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Frazer, A; Mendels, J; Savage, DD | 1 |
| Follender, AB; Hughes, PL; Jermain, DM | 1 |
| Hawkins, JW | 1 |
| deVries, J; Suchowersky, O | 1 |
| deVries, JD; Suchowersky, O | 1 |
| Buckholtz, NS; Sparks, DL | 1 |
| Garcia-Monco, JC; Gomez Beldarrain, M; Padierna, A | 1 |
| Waters, CH | 1 |
| Chamontin, B; Llau, ME; Montastruc, JL; Rascol, A; Rascol, O; Senard, JM; Tran, MA | 1 |
| Azmitia, EC; Gu, XF | 1 |
| Iacono, RP; Toyama, SC | 1 |
| Andrews, AM; Murphy, DL | 1 |
| Adler, L; Huether, G; Poeggeler, B; Rüther, E | 1 |
| Asnis, J; Patel, SV; Tariot, PN | 1 |
| Klenk-Majewska, B; Lupina, T; Ossowska, G; Pietrasiewicz, T; Zebrowska-Lupina, I | 1 |
| Oakley, F; Sunderland, T | 1 |
| Marsh, C; Preskorn, SH; Shad, MU | 1 |
| Bilbao Garay, J; Castilla Castellano, V; Dhimes Tejada, P; Mesa Plaza, N | 1 |
| Brown, AW; Hrometz, SL; Nichols, DE; Sprague, JE | 1 |
| Carey, GJ; Gold, LH; Nielsen, DM | 1 |
| Csoka, AB; Shipko, S | 1 |
| Cano, E; Fraiz, N; Orallo, F; Yáñez, M | 1 |
| Blaugrund, E; Cohen, S; Eliash, S; Fine, T; Litinetsky, L; Speiser, Z | 1 |
| Preskorn, SH | 1 |
| Borowsky, R; Hoekstra, HE; Jeffery, WR; Kay, EH; Kowalko, JE; Linden, TA; Peterson, BK; Rohner, N; Rompani, SB; Tabin, CJ; Weber, J; Yoshizawa, M | 1 |
| Fink-Gremmels, J; Schrickx, JA | 1 |
| Forsblad, A; Hashemian, S; Jacobsson, SO; Popova, D | 1 |
| Chamanara, M; Dehpour, AR; Nikoui, V; Norouzi-Javidan, A; Ostadhadi, S; Shakiba, S; Zolfaghari, S | 1 |
4 review(s) available for fluoxetine and selegiline
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid | 2008 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Serotonin syndrome: report of a fatal case and review of the literature].
Topics: Aged; Antiparkinson Agents; Carbidopa; Depressive Disorder, Major; Drug Combinations; Drug Synergism; Fatal Outcome; Fluoxetine; Humans; Levodopa; Male; Parkinson Disease; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome | 2002 |
2 trial(s) available for fluoxetine and selegiline
| Article | Year |
|---|---|
Fluoxetine and selegiline--lack of significant interaction.
Topics: Adult; Aged; Aged, 80 and over; Depressive Disorder; Drug Interactions; Female; Fluoxetine; Humans; Male; Middle Aged; Parkinson Disease; Selegiline | 1994 |
Assessment of motor and process skills as a measure of IADL functioning in pharmacologic studies of people with Alzheimer's disease: a pilot study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Motor Skills; Neuropsychological Tests; Nootropic Agents; Physostigmine; Pilot Projects; Problem Solving; Psychometrics; Reproducibility of Results; Selegiline; Treatment Outcome | 1997 |
34 other study(ies) available for fluoxetine and selegiline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery.
Topics: Animals; Brain; Central Nervous System Agents; Dialysis; Hydrophobic and Hydrophilic Interactions; In Vitro Techniques; Mice; Models, Statistical; Protein Binding; Quantitative Structure-Activity Relationship; Rats | 2007 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on 3H-serotonin receptor binding in rat brain.
Topics: Animals; Brain; Clomipramine; Clorgyline; Fluoxetine; Male; Monoamine Oxidase Inhibitors; Rats; Receptors, Serotonin; Selegiline; Serotonin Antagonists | 1979 |
Potential fluoxetine-selegiline interaction.
Topics: Aged; Ataxia; Depression; Drug Interactions; Female; Fluoxetine; Humans; Parkinson Disease; Selegiline | 1992 |
Nonsedating treatments for Alzheimer's patients with behavioral problems.
Topics: Alzheimer Disease; Buspirone; Fluoxetine; Humans; Selegiline; Sleep; Trazodone | 1992 |
Possible interactions between deprenyl and prozac.
Topics: Drug Interactions; Female; Fluoxetine; Humans; Middle Aged; Parkinson Disease; Selegiline | 1990 |
Interaction of fluoxetine and selegiline.
Topics: Bipolar Disorder; Depressive Disorder; Drug Synergism; Drug Therapy, Combination; Female; Fluoxetine; Humans; Hypertension; Middle Aged; Selegiline | 1990 |
Effects of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (6-MeO-THbetaC) on audiogenic seizures in DBA/2J mice.
Topics: 5-Hydroxytryptophan; Acoustic Stimulation; Animals; Benzofurans; Carbolines; Citalopram; Clomipramine; Clorgyline; Fluoxetine; Harmine; Indoles; Methoxydimethyltryptamines; Mice; Mice, Inbred DBA; N,N-Dimethyltryptamine; Pargyline; Propylamines; Quipazine; Seizures; Selegiline | 1980 |
Selegiline, fluoxetine, and depression in Parkinson's disease.
Topics: Aged; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Parkinson Disease; Selegiline | 1995 |
Pseudophaeochromocytoma in parkinsonian patient treated with fluoxetine plus selegiline.
Topics: Adrenal Gland Neoplasms; Adult; Catecholamines; Diagnosis, Differential; Drug Interactions; Female; Fluoxetine; Humans; Hypertension; Parkinson Disease; Pheochromocytoma; Selegiline | 1993 |
Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Brain Stem; Carrier Proteins; Cells, Cultured; Clorgyline; Female; Fluoxetine; Membrane Glycoproteins; Membrane Transport Proteins; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Neurons; Nimodipine; p-Chloroamphetamine; Pregnancy; Rats; Rats, Sprague-Dawley; Reserpine; Selegiline; Serotonin; Serotonin Plasma Membrane Transport Proteins | 1993 |
Is it safe to combine a selective serotonin reuptake inhibitor with selegiline?
Topics: 1-Naphthylamine; Drug Interactions; Drug Therapy, Combination; Fluoxetine; Humans; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline | 1994 |
2'-NH2-MPTP in Swiss Webster mice: evidence for long-term (6-month) depletions in cortical and hippocampal serotonin and norepinephrine, differential protection by selective uptake inhibitors or clorgyline and functional changes in central serotonin neuro
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Cerebral Cortex; Clorgyline; Desipramine; Fluoxetine; Hippocampus; Male; Mice; Monoamine Oxidase Inhibitors; MPTP Poisoning; Neurotransmitter Uptake Inhibitors; Norepinephrine; Paroxetine; Selegiline; Serotonin; Serotonin Receptor Agonists; Synaptic Transmission; Time Factors | 1993 |
Effects of indirectly acting 5-HT receptor agonists on circulating melatonin levels in rats.
Topics: 3,4-Methylenedioxyamphetamine; Animals; Fenfluramine; Fluoxetine; Injections, Intraperitoneal; Male; Melatonin; Pargyline; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Receptor Agonists; Tryptophan | 1993 |
L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease.
Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Attention; Carbamazepine; Depression; Drug Interactions; Drug Therapy, Combination; Expressed Emotion; Female; Fluoxetine; Humans; Huntington Disease; Impulsive Behavior; Monoamine Oxidase Inhibitors; Movement; Selegiline; Violence | 1996 |
ACTH 4-9 analogue facilitates the antiimmobility effect of antidepressants and dopamine agonists in swimming rats.
Topics: Adrenocorticotropic Hormone; Animals; Antidepressive Agents; Antidepressive Agents, Second-Generation; Dopamine Agonists; Exploratory Behavior; Fear; Fluoxetine; Fluvoxamine; Monoamine Oxidase Inhibitors; Motor Activity; Peptide Fragments; Piribedil; Quinpirole; Rats; Rats, Wistar; Selegiline; Swimming | 1997 |
The economic consequences of a drug-drug interaction.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Depression; Drug Interactions; Female; Fluoxetine; Haloperidol; Health Care Costs; Humans; Olanzapine; Parkinson Disease; Pirenzepine; Selegiline; Trihexyphenidyl | 2001 |
3,4-methylenedioxymethamphetamine (MDMA, ecstasy)-mediated production of hydrogen peroxide in an in vitro model: the role of dopamine, the serotonin-reuptake transporter, and monoamine oxidase-B.
Topics: Cell Line, Tumor; Cell Survival; Choriocarcinoma; Dopamine; Drug Interactions; Female; Fluoxetine; Hallucinogens; Humans; Hydrogen Peroxide; Membrane Glycoproteins; Membrane Transport Proteins; Models, Biological; Monoamine Oxidase; Monoamine Oxidase Inhibitors; N-Methyl-3,4-methylenedioxyamphetamine; Nerve Tissue Proteins; Pregnancy; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Plasma Membrane Transport Proteins; Time Factors | 2004 |
Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice.
Topics: Animals; Antidepressive Agents; Clorgyline; Desipramine; Dose-Response Relationship, Drug; Fluoxetine; Hindlimb Suspension; Male; Mice; Morpholines; Motor Activity; Paroxetine; Pyrazoles; Pyrimidines; Pyrroles; Reboxetine; Receptors, Corticotropin-Releasing Hormone; Selegiline; Swimming; Tranylcypromine; Triazines | 2004 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonists; Dopamine Uptake Inhibitors; Ergolines; Female; Fluoxetine; Humans; Male; Monoamine Oxidase Inhibitors; Piperazines; Plants, Medicinal; Purines; Selective Serotonin Reuptake Inhibitors; Selegiline; Sertraline; Sexual Dysfunctions, Psychological; Sildenafil Citrate; Sleep Initiation and Maintenance Disorders; Sulfones; Testosterone; Time Factors; Treatment Outcome; Vasodilator Agents | 2006 |
(-)-Trans-epsilon-viniferin, a polyphenol present in wines, is an inhibitor of noradrenaline and 5-hydroxytryptamine uptake and of monoamine oxidase activity.
Topics: Animals; Benzofurans; Blood Platelets; Brain; Cell Line; Citalopram; Clorgyline; Dose-Response Relationship, Drug; Fluoxetine; Humans; Imipramine; Iproniazid; Isoenzymes; Male; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Norepinephrine; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Selegiline; Serotonin; Stilbenes; Synaptosomes; Tritium; Wine | 2006 |
Differential behavioral syndrome evoked in the rats after multiple doses of SSRI fluoxetine with selective MAO inhibitors rasagiline or selegiline.
Topics: Animals; Behavior, Animal; Brain; Drug Therapy, Combination; Fluoxetine; Indans; Male; Methamphetamine; Monoamine Oxidase Inhibitors; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin Syndrome | 2008 |
Multiple medication use presenting as Parkinson's dementia complex: a message from Titanic.
Topics: Aged; Anti-Infective Agents; Antiparkinson Agents; Antipsychotic Agents; Bacteriuria; Ciprofloxacin; Dementia; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Fluoxetine; Haloperidol; Hospitalization; Humans; Hypnotics and Sedatives; Lorazepam; Parkinson Disease; Psychomotor Agitation; Selegiline; Trihexyphenidyl | 2008 |
Loss of schooling behavior in cavefish through sight-dependent and sight-independent mechanisms.
Topics: Adaptation, Physiological; Animals; Behavior, Animal; Biological Evolution; Brain; Caves; Characidae; Dopamine; Fluoxetine; Lateral Line System; Lens, Crystalline; Monoamine Oxidase Inhibitors; Neurotransmitter Agents; Quantitative Trait Loci; Selection, Genetic; Selective Serotonin Reuptake Inhibitors; Selegiline; Serotonin; Vision, Ocular | 2013 |
Inhibition of P-glycoprotein by psychotherapeutic drugs in a canine cell model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Clomipramine; Dogs; Fluoxetine; Gene Expression Regulation; Monoamine Oxidase Inhibitors; Selective Serotonin Reuptake Inhibitors; Selegiline | 2014 |
Non-Serotonergic Neurotoxicity by MDMA (Ecstasy) in Neurons Derived from Mouse P19 Embryonal Carcinoma Cells.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Survival; Clorgyline; Embryonal Carcinoma Stem Cells; Fluoxetine; Gene Expression; Membrane Potential, Mitochondrial; Mice; Monoamine Oxidase; N-Methyl-3,4-methylenedioxyamphetamine; Neurons; Selegiline; Serotonin Plasma Membrane Transport Proteins | 2016 |
The role of nitric oxide-cGMP pathway in selegiline antidepressant-like effect in the mice forced swim test.
Topics: Animals; Antidepressive Agents; Arginine; Cyclic GMP; Drug Synergism; Fluoxetine; Guanidines; Hippocampus; Immobility Response, Tonic; Indazoles; Male; Methylene Blue; Mice; Motor Activity; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitrites; Prefrontal Cortex; Selegiline; Signal Transduction; Sildenafil Citrate; Swimming | 2018 |